RA Harrington
Impact in
- Gastroenterology top 10%
- Gastrointestinal motility and disorders
-
- Venous Thromboembolism Diagnosis and Management
Papers in
-
- Venous Thromboembolism Diagnosis and Management 6
-
- Acute Myocardial Infarction Research 10
- Antiplatelet Therapy and Cardiovascular Diseases 9
- Atrial Fibrillation Management and Outcomes 3
- Co-authors
- Joseph A. LinkewichCindy W. HamiltonJohn A. RomankiewiczRex N. BrogdenR.C. HeelJames G. JollisFrans Van de WerfEric J. Topol
- Journals
- Journal of the American College of Cardiology (9 papers)Circulation (6 papers)Drugs (1 paper)European Heart Journal (1 paper)ACC Current Journal Review (2 papers)
- Partner nations
- CanadaUnited States
In The Last Decade
RA Harrington
19 papers receiving 368 citations
Peers
Comparison fields: 5 of 83
- Gastroenterology 47
- Internal Medicine 26
- Anesthesiology and Pain Medicine 28
- Surgery 191
- Cardiology and Cardiovascular Medicine 92
Countries citing papers authored by RA Harrington
This map shows the geographic impact of RA Harrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RA Harrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RA Harrington more than expected).
Fields of papers citing papers by RA Harrington
This network shows the impact of papers produced by RA Harrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RA Harrington. The network helps show where RA Harrington may publish in the future.
Co-authors
The 25 scholars most cited alongside RA Harrington, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Health Economics in the PLATelet Inhibition and Patient Outcomes (PLATO) Randomized Trial: Report on Within Trial Resource Use Patterns | 2010 | 1 |
| 2 | 2004 | 31 | |
| 3 | Higher Aspirin Dose is Associated with Reduced Mortality and More Serious Bleeding in Patients with Recent Cerebrovascular or Coronary Ischemic Events: Insights from the BRAVO Trial | 2003 | 1 |
| 4 | Optimal dosing of a glycoprotein IIb/IIIa antagonist with simplified renal-based algorithm: pharmacodynamic and clinical findings from PARAGON B | 2001 | 0 |
| 5 | Frequency, Patient Characteristics, and Outcomes of Mild to Moderate Heart Failure Complicating ST-Segment Elevation Acute Myocardial Infarction: Lessons from Four International Fibrinolytic Therapy Trials | 2001 | 1 |
| 6 | Diabetes doubles the risk of death among patients presenting with acute coronary syndromes: insights from SYMPHONY, a large international trial | 2001 | 1 |
| 7 | Acute Coronary Syndrome Patients Benefit from Platelet Glycoprotein IIb/IIIa Inhibition as Part of an Initially Medical Treatment Strategy: Results of a Meta-Analysis of Phase III Randomized Trials | 2001 | 0 |
| 8 | The ST-Depression >=2 mm sign: an ominous prognosis in acute coronary syndromes | 1999 | 1 |
| 9 | Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study). | 1999 | 5 |
| 10 | Plasma concentration of lamifiban and glycoprotein IIb-IIIa receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A | 1998 | 4 |
| 11 | 1998 | 0 | |
| 12 | 1998 | 7 | |
| 13 | 1998 | 5 | |
| 14 | 1998 | 4 | |
| 15 | Relationship of Outcomes to Treatment with Lamifiban in Patients Undergoing PTCA: Analysis of PARAGON A | 1997 | 3 |
| 16 | Combining IIb/IIIa Inhibition and Heparin for Acute Coronary Syndromes: Evidence of a Gradient for Bleeding Hazard from the PARAGON Randomized Factorially Designed Trial | 1997 | 2 |
| 17 | Delaying and Preventing Ischemic Events in Patients with Acute Coronary Syndromes Using the Platelet Glycoprotein IIb/IIIa Inhibitor Lamifiban | 1997 | 8 |
| 18 | Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor lamifiban in patients with non ST segment elevation in acute coronary syndromes | 1997 | 4 |
| 19 | More Complete and Stable Reperfusion with Platelet IIb/IIIa Antagonism Plus Thrombolysis for AMI: The PARADIGM Trial | 1996 | 16 |
| 20 | 1983 | 286 |
About RA Harrington
RA Harrington is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine, Hematology, Clinical Biochemistry and Surgery, having authored 22 papers that have together received 391 indexed citations. Recurring topics across this work include Acute Myocardial Infarction Research (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers), Venous Thromboembolism Diagnosis and Management (6 papers), Heparin-Induced Thrombocytopenia and Thrombosis (3 papers), Atrial Fibrillation Management and Outcomes (3 papers), Nausea and vomiting management (1 paper), Genomics and Rare Diseases (1 paper) and Drug Transport and Resistance Mechanisms (1 paper). The work is most often cited by research in Gastroenterology (47 citations), Internal Medicine (26 citations), Anesthesiology and Pain Medicine (28 citations), Surgery (191 citations) and Cardiology and Cardiovascular Medicine (92 citations). RA Harrington has collaborated with scholars based in Canada and United States. Frequent co-authors include Joseph A. Linkewich, Cindy W. Hamilton, John A. Romankiewicz, Rex N. Brogden, R.C. Heel, James G. Jollis, Frans Van de Werf, Eric J. Topol, Alexis Rames and William Hui. Their work appears in journals such as Journal of the American College of Cardiology, Circulation, Drugs, European Heart Journal and ACC Current Journal Review.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.